Q&A Panel Discussion: Ethics & Trial Design
Time: 2:55 pm
day: Day Two
• Enrolment criteria for pre-existing immunity titer and how this shifts from company to company
• Forward thinking drug development trial design with the patient in mind
• How has COVID-19 affected gene therapy trials? What can be learned from this for future trial design?